BioSpace News Archive

Harrow Health, Inc. (NASDAQ: HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time to discuss the financial results and recent business developments.

Intellia Therapeutics today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.

TYMLOS ® U.S. net sales grew to $56 million in the fourth quarter of 2019, totaling $173M for full-year 2019, exceeding the Company’s guidance of $168 to 172M TYMLOS exited 2019 with majority share in new patients 1 , on track for market leadership in 2020 2020 TYMLOS U.S. net revenue expected to be between $220 and $235M and full-year cash burn expected to be below $80M Recruitment of three Phase 3 studies is advancing and expected to be completed in 2020, with anticipate

Albireo Pharma, Inc. announced its support for Rare Disease Day 2020 and reaffirms its commitment to patients and families living with biliary atresia, Alagille syndrome, progressive familial intrahepatic cholestasis and other rare cholestatic diseases.

Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced that the U.S. Food and Drug Administration has extended the review period for the New Drug Application for FINTEPLA® for the treatment of seizures associated with Dravet syndrome.

Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for Crysvita® for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report fiscal 2019 financial results on Thursday, March 5, 2020 at 4:45PM EST

Digirad Corporation will release its financial results for the fourth quarter and year ended December 31, 2019 before the market opens on Friday, March 6, 2020.

IQ4I Research & Consultancy published a new report on “Medical Device Contract Manufacturing Global Market – Forecast To 2026.”

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific.